Founded in 1982, Cosmogen has become an international expert in the application and design of premium, value-added primary packaging, offering brands customized, reliable, responsible, and operational turnkey solutions. More recently, Cosmogen entered the pharmaceutical industry, with a range of packaging dedicated to OTC products.
Under the lead of Priscille Allais, its President and CEO since 2019, Cosmogen has experienced strong growth based on a strategy of “reconciling economic performance, team well-being, and sustainable innovation,” formalized by its status as a company with a mission in 2022.
Weinberg Capital Partners is recognized for “its expertise in supporting and accelerating the development of SMEs.” The investment fund focuses on five areas: team structuring, external growth, digitalization, internationalization, and ESG support.
Allais said,
“The teams are delighted, fully committed, and motivated to lead this new stage of growth with Weinberg Capital Partners, whose investment is a validation of our vision and strategy. It will enable us to accelerate Cosmogen’s development while remaining true to what makes us successful today: our culture, our values, our capacity for innovation, our high standards, and our dedication to our customers.”
Paul Cordahi, director at Weinberg Capital Partners, commented,
“Priscille Allais has done a remarkable job of positioning Cosmogen as a unique player in a dynamic market. Her reputation with major brands and her wealth of expertise should enable Cosmogen to continue its strong growth trajectory. It’s this first-rate ‘customer capital’ that won us over. We have already identified opportunities for external growth, with the aim of strengthening the company internationally.”
